Millennium Management’s Protagonist Therapeutics PTGX Stock Holding History

Millennium Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-35,000	Closed	-$1.35M	–	6302
2024 Q4	$1.35M	Buy	+35,000	New	+$1.53M	﹤0.01%	3954
2023 Q3	–	Sell	-30,500	Closed	-$842K	–	6464
2023 Q2	$842K	Buy	+30,500	New	+$763K	﹤0.01%	4176
2022 Q3	–	Sell	-30,000	Closed	-$237K	–	7408
2022 Q2	$237K	Hold	30,000	–	–	﹤0.01%	5544
2022 Q1	$710K	Buy	30,000 +20,000	+200%	+$563K	﹤0.01%	4850
2021 Q4	$342K	Sell	10,000 -50,000	-83%	-$1.58M	﹤0.01%	5410
2021 Q3	$1.06M	Buy	+60,000	New	+$2.56M	﹤0.01%	4607

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Millennium Management's PTGX Position: Q1 2026 in Review

Millennium Management sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 17,391 shares — an estimated $1.52M sold.

Millennium Management first reported a position in PTGX in Q2 2017 and held it in 31 quarters. The position peaked at $33.2M in Q2 2024. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

Millennium Management reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
Millennium Management sold 17,391 Protagonist Therapeutics shares in Q1 2026, an estimated $1.52M.
Millennium Management first reported a position in Protagonist Therapeutics in Q2 2017 and held it in 31 quarters.
Millennium Management's Protagonist Therapeutics position peaked at $33.2M in Q2 2024.
317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.